Galmed Pharmaceuticals Ltd.
GLMD
$1.56
$0.00430.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 3.40M | 3.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 6.24M | 6.24M |
| Operating Income | -- | -- | -- | -6.24M | -6.24M |
| Income Before Tax | -- | -- | -- | -5.88M | -5.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -5.88 | -5.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -5.88M | -5.88M |
| EBIT | -- | -- | -- | -6.24M | -6.24M |
| EBITDA | -- | -- | -- | -6.15M | -6.15M |
| EPS Basic | -- | -- | -- | -26.64 | -26.15 |
| Normalized Basic EPS | -- | -- | -- | -15.19 | -14.89 |
| EPS Diluted | -- | -- | -- | -26.64 | -26.15 |
| Normalized Diluted EPS | -- | -- | -- | -15.19 | -14.89 |
| Average Basic Shares Outstanding | -- | -- | -- | 1.52M | 1.67M |
| Average Diluted Shares Outstanding | -- | -- | -- | 1.52M | 1.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |